stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(3.90) | (9.24) | — | — | |
P/B ratio |
0.00 | 0.00 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
0.00 | 0.00 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(1.04) | (1.90) | — | — | |
EV/FCF |
(1.04) | (1.90) | — | — | |
Quick Ratio |
0.39 | 0.35 | 0.51 | 0.29 | |
Current Ratio |
0.66 | 0.51 | 0.65 | 0.65 | |
Net Debt/EBITDA |
0.55 | 1.20 | 1.34 | 0.32 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.01 | 0.69 | 0.92 | 0.50 | |
Interest Coverage |
(30.27) | (16.55) | (44.94) | (1,914.25) | |
Research and Development Expense of Revenue |
2,480.99% | 2,197.86% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8,940.91% | 8,375.40% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,028.93% | 2,679.14% | 0.00% | 0.00% | |
Graham Net Nets |
(0.17) | (0.25) | — | — | |
Graham Number |
16.80 | 52.07 | — | — | |
Earnings Yield |
(118.97%) | (71.94%) | — | — | |
Free Cash Flow Yield |
(80.90%) | (43.70%) | — | — | |
Revenue per Share |
0.04 | 0.04 | 0.00 | 0.00 | |
Operating CF per Share |
(4.12) | (3.05) | (5.14) | (2.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.12) | (3.05) | (5.14) | (2.55) | |
Cash per Share |
2.73 | 5.04 | 8.23 | 1.60 | |
Shareholders Equity per Share |
(0.66) | (5.94) | (3.98) | 0.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.66) | (5.94) | (3.98) | 0.13 | |
Free Cash Flow |
(2.29) | (1.43) | (2.37) | (1.15) | |
Working Capital |
(1.33) | (3.32) | (2.57) | (0.89) | |
Net Current Asset Value |
(1.54) | (3.32) | (2.57) | (0.89) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
0.75 | 0.38 | 0.52 | 0.57 | |
Average Assets |
3.84 | 4.46 | 5.88 | 1.33 | |
Average Common Equity |
0.49 | 0.14 | 1.17 | (2.85) |
Columns are period end dates